Nivolumab (anti-PD-1)

製品コードA2002 別名: BMS-936558, ONO-4538, MDX-1106

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

Nivolumab (anti-PD-1)
サイズ 価格(税別) 在庫状況
1mg JPY 44500 国内在庫あり
1mg*5 JPY 146500 お問い合わせ
5mg JPY 146500 国内在庫あり
1mg*25 JPY 445500 お問い合わせ

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(60)

質量管理及び製品安全説明書

現在のバッチを見る: 純度: 99.87% タンパク質濃度: 8.8 mg/ml 内毒素: <1 EU/mg
99.87

PD-1/PD-L1阻害剤の選択性比較

生物活性

製品説明 Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
同型 Human IgG4
Targets
PD-1/PD-L1 interaction [2]
(Cell-free assay)
PD-1/PD-L2 interaction [2]
(Cell-free assay)
2.52 nM 2.59 nM
In Vitro
In Vitro

The cell binding ratio of 125I-Nivolumab and 125I-Nivolumab-DTPA to PD-1 is 13.78 ± 2.90% and 10.22 ± 2.62%, respectively. Conjugating of DTPA does not affect targeting of Nivolumab to PD-1 in vitro.[1]

細胞実験

Splenocytes were isolated from the spleens obtained from humanized PD-1 over-expressing mice following standard protocol. 125I labeled Nivolumab and Nivolumab-DTPA, respectively. To perform co-culture, 125I-Nivolumab and 125I-Nivolumab-DTPA (0.37 MBq/µg) were added to the freshly isolated splenocytes (1×106 cells) grown in 6-well plates, respectively. After incubation for 12 h at 4°C, cells were collected after rinsing three times with PBS. 125I radioactivity was determined in a gamma counter to evaluate their binding efficiency to PD-1.

In Vivo
In Vivo

In SPECT images, lesions with high 99mTc-DTPA-nivolumab uptake and relatively clear background are shown at 6 h. Thereafter, the suspected intestinal thickening in Gd-free T1WI is observed at 2 h after the addition of Gd-DTPA-nivolumab.[1]

動物試験

Animal Models: CRC mouse models (highly expressed human PD-1 antigen)
Dosages: 11.1 MBq/10 μg
Administration: i.v.
Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883027/
 

製品説明

CAS No. 946414-94-4
Formulation PBS buffer, pH 7.2
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Sterility 5.82 mg/ml

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問:1:
How to store the antibody?

回答:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: Nivolumab (anti-PD-1)を買う | Nivolumab (anti-PD-1) ic50 | Nivolumab (anti-PD-1)供給者 | Nivolumab (anti-PD-1)を購入する | Nivolumab (anti-PD-1)費用 | Nivolumab (anti-PD-1)生産者 | オーダーNivolumab (anti-PD-1) | Nivolumab (anti-PD-1)化学構造 | Nivolumab (anti-PD-1)分子量 | Nivolumab (anti-PD-1)代理店